初始结果
The OS was reported in all eight trials.
在所有8项试验中都报道了整体生存率（OS）。
The corresponding HR was reported in three trials, obtained through correspondence with the author in one trial [24], and extrapolated from reconstructed approximate individual patient data from published Kaplan-Meier curves in two trials [27,29].
在三个试验中报道了相应的风险比（HR），通过与作者在其中一个试验中的通信获得，并从两个试验中发表的Kaplan-Meier曲线重建的近似个体患者数据推断。
We could not use the data from two trials in our analyses as they either solely provided the median survival or the survival rates at six and 12 months , respectively.
来自两个试验的数据不能用，因为它们要么分别提供了中位生存或6个月和12个月时的生存率。
Y90-TARE was not associated with differences in overall survival (HR 0.99 [ 95% CI 0.81–1.21], six trials, I² = 77.6%, Fig 3) compared to standard of care.
与标准治疗相比，Y90-TARE总生存率的差异无关 ( HR0.99 [ 95% CI 0.81–1..21]，6次试验，I²=77.6%
Our results were comparable in our subgroup analyses (Table 2).
我们的结果在我们的亚组分析中具有可比性（表2）。
关于HR：HR 值的解释与 RR 几乎一致，即表示暴露组患病的概率为非暴露组的多少倍。但是与 logistic 回归不同的是，Cox 模型除了可以校正混杂因素外，还考虑了结局事件发生的时间。从时间到事件森林图分析 Forest plot of time-to-event outcomes
啥叫“考虑了时间因素的 RR？我们可以理解为：与不吸烟人群相比，吸烟人群在 30 年内患肺癌的风险是不吸烟人群的10倍。注意“30 年内患肺癌的风险”，这是一个很含糊的说法：有人可能在随访开始第二年就发生肺癌，有人可能到随访快结束时（第三十年）才发生肺癌。如果构建四格表，这两个肺癌是同等看待的，但实际上，这两种肺癌的“社会危害性”显然是不能相提并论的！毕竟后者很有可能会多活二十多年。因此，我们在考虑结局事件是否发生的同时，往往还要考虑结局事件发生的时间！这就是 HR 存在的价值！
Secondary outcomes
Time to radiological progressionThe time to radiological progression was reported as two different outcomes in the included trials: progression-free survival and/or time to progression.
到放射学进展的时间在纳入的试验中，放射学进展的时间被报告为两种不同的结果：无进展生存期和/或到进展的时间。
Progression-free survival was reported in four trials
在4项试验中报道了无进展生存期，
The corresponding HR was reported in two trials] and extrapolated from published Kaplan-Meier curves in one trial [27].
两个试验中报道了相应的HR，并从一项试验中发表的Kaplan-Meier曲线推算。
We could not use the data in our quantitative analyses in another trial [25] providing solely a median progression-free survival with its 95% CI.
我们不能在另一项试验的定量分析中使用这些数据，仅提供其95%可信区间的中位数无进展生存率。
The time to progression was reported in five trials
5项试验报道了进展的时间。
The corresponding HR were reported in two trials [23,29], obtained through author correspondence in one trial [24] and extrapolated using a previously described algorithm in one trial [27], but with only partial data.
相应的HR在两个试验[23,29]中被报道，通过一个试验[24]中的作者通信获得，并在一个试验[27]中使用前面描述的算法进行外推，但只有部分数据。
Y90-TARE yielded no differences in progression-free survival (Fig 3, Table A in S3 Appendix) and time to progression (Fig 3).
Y90-TARE在无进展生存期(图3，S3附录中的表A)和进展时间（图3）方面没有任何差异。
Y90-TARE yielded a significantly longer time to progression in the glass microsphere subgroup (HR 0.
Y90-TARE在玻璃微球亚组中产生的进展时间明显更长(HR0。
23 [95% CI 0.
23[95%CI0.
12–0.
12–0.
|
|
